JP2011516420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516420A5 JP2011516420A5 JP2011502011A JP2011502011A JP2011516420A5 JP 2011516420 A5 JP2011516420 A5 JP 2011516420A5 JP 2011502011 A JP2011502011 A JP 2011502011A JP 2011502011 A JP2011502011 A JP 2011502011A JP 2011516420 A5 JP2011516420 A5 JP 2011516420A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- aryl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 125000002723 alicyclic group Chemical group 0.000 claims description 18
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims description 13
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- -1 heteroalicyclic Chemical group 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000001118 alkylidene group Chemical group 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000004001 thioalkyl group Chemical group 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 125000002015 acyclic group Chemical group 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 102000014461 Ataxins Human genes 0.000 claims description 2
- 108010078286 Ataxins Proteins 0.000 claims description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 206010062264 Congenital hyperthyroidism Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013883 Dwarfism Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 2
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims description 2
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims description 2
- 208000000038 Hypoparathyroidism Diseases 0.000 claims description 2
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 claims description 2
- 208000008955 Mucolipidoses Diseases 0.000 claims description 2
- 206010072928 Mucolipidosis type II Diseases 0.000 claims description 2
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 201000005660 Protein C Deficiency Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 2
- 208000022292 Tay-Sachs disease Diseases 0.000 claims description 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 2
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 229960005475 antiinfective agent Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 201000010064 diabetes insipidus Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims description 2
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 208000000638 myeloperoxidase deficiency Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 108010040003 polyglutamine Proteins 0.000 claims description 2
- 229920000155 polyglutamine Polymers 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 150000001260 acyclic compounds Chemical group 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 0 C*1C2C(C)(C)CCC12 Chemical compound C*1C2C(C)(C)CCC12 0.000 description 9
- 238000000034 method Methods 0.000 description 5
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 4
- DYQQZIVYJMLWTD-UHFFFAOYSA-N CC(C)N(CCOC(C)c(cccc1)c1OC)C(C)C Chemical compound CC(C)N(CCOC(C)c(cccc1)c1OC)C(C)C DYQQZIVYJMLWTD-UHFFFAOYSA-N 0.000 description 1
- ITAXXPAEDHHVDK-UHFFFAOYSA-N CC(c(cccc1)c1OC)OCCN1CCCCC1 Chemical compound CC(c(cccc1)c1OC)OCCN1CCCCC1 ITAXXPAEDHHVDK-UHFFFAOYSA-N 0.000 description 1
- ODENTAMIJLBWSF-UHFFFAOYSA-N CC(c1ccccc1OC)N1CC(C)OC(C)C1 Chemical compound CC(c1ccccc1OC)N1CC(C)OC(C)C1 ODENTAMIJLBWSF-UHFFFAOYSA-N 0.000 description 1
- IPEOALIFMRMNRT-UHFFFAOYSA-N CC(c1ccccc1OC)N1CCCC1 Chemical compound CC(c1ccccc1OC)N1CCCC1 IPEOALIFMRMNRT-UHFFFAOYSA-N 0.000 description 1
- YUMRNIILPQNWDO-UHFFFAOYSA-N CC(c1ccccc1OC)N1CCN(CCO)CC1 Chemical compound CC(c1ccccc1OC)N1CCN(CCO)CC1 YUMRNIILPQNWDO-UHFFFAOYSA-N 0.000 description 1
- CBVDDSUFZQULQL-UHFFFAOYSA-N CC(c1ccccc1OC)N1CCN(CCOC)CC1 Chemical compound CC(c1ccccc1OC)N1CCN(CCOC)CC1 CBVDDSUFZQULQL-UHFFFAOYSA-N 0.000 description 1
- WSDVHWASCHELJA-UHFFFAOYSA-N CC(c1ccccc1OC)N1CCOCC1 Chemical compound CC(c1ccccc1OC)N1CCOCC1 WSDVHWASCHELJA-UHFFFAOYSA-N 0.000 description 1
- PYGFIGLUHGUOGN-UHFFFAOYSA-N CCN(CC)C(C)c(cccc1)c1OC Chemical compound CCN(CC)C(C)c(cccc1)c1OC PYGFIGLUHGUOGN-UHFFFAOYSA-N 0.000 description 1
- NUDVJQOVBFONPG-UHFFFAOYSA-N CCc(c(Cl)ccc1)c1Cl Chemical compound CCc(c(Cl)ccc1)c1Cl NUDVJQOVBFONPG-UHFFFAOYSA-N 0.000 description 1
- HYFLWBNQFMXCPA-UHFFFAOYSA-N CCc1ccccc1C Chemical compound CCc1ccccc1C HYFLWBNQFMXCPA-UHFFFAOYSA-N 0.000 description 1
- CVGAWKYSRYXQOI-UHFFFAOYSA-N CCc1ccccc1Cl Chemical compound CCc1ccccc1Cl CVGAWKYSRYXQOI-UHFFFAOYSA-N 0.000 description 1
- XQFJDFIHJKPUEL-UHFFFAOYSA-N CN(C)c(cccc1)c1OC Chemical compound CN(C)c(cccc1)c1OC XQFJDFIHJKPUEL-UHFFFAOYSA-N 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N CNCc1ccccc1 Chemical compound CNCc1ccccc1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- KNZWULOUXYKBLH-UHFFFAOYSA-N CNc(cccc1)c1OC Chemical compound CNc(cccc1)c1OC KNZWULOUXYKBLH-UHFFFAOYSA-N 0.000 description 1
- WFWDIWPWCNUWLM-UHFFFAOYSA-N COc1ccccc1C(N1CCCCC1)I Chemical compound COc1ccccc1C(N1CCCCC1)I WFWDIWPWCNUWLM-UHFFFAOYSA-N 0.000 description 1
- WGRPQCFFBRDZFV-UHFFFAOYSA-N Cc1cccc(C(N)=O)c1 Chemical compound Cc1cccc(C(N)=O)c1 WGRPQCFFBRDZFV-UHFFFAOYSA-N 0.000 description 1
- ZDBWNRRPANCKMV-UHFFFAOYSA-N IOCc1ccccc1 Chemical compound IOCc1ccccc1 ZDBWNRRPANCKMV-UHFFFAOYSA-N 0.000 description 1
- POHJRJNCZQENQG-UHFFFAOYSA-N O=C1NC=CC(I)=C1 Chemical compound O=C1NC=CC(I)=C1 POHJRJNCZQENQG-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4077608P | 2008-03-31 | 2008-03-31 | |
| US61/040,776 | 2008-03-31 | ||
| PCT/US2009/038203 WO2009123896A1 (en) | 2008-03-31 | 2009-03-25 | Pyridyl derivatives as cftr modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014018199A Division JP5930487B2 (ja) | 2008-03-31 | 2014-02-03 | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011516420A JP2011516420A (ja) | 2011-05-26 |
| JP2011516420A5 true JP2011516420A5 (cg-RX-API-DMAC10.html) | 2013-03-21 |
| JP5622285B2 JP5622285B2 (ja) | 2014-11-12 |
Family
ID=40790781
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502011A Active JP5622285B2 (ja) | 2008-03-31 | 2009-03-25 | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
| JP2014018199A Active JP5930487B2 (ja) | 2008-03-31 | 2014-02-03 | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
| JP2015088075A Withdrawn JP2015131860A (ja) | 2008-03-31 | 2015-04-23 | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014018199A Active JP5930487B2 (ja) | 2008-03-31 | 2014-02-03 | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
| JP2015088075A Withdrawn JP2015131860A (ja) | 2008-03-31 | 2015-04-23 | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
Country Status (17)
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| ZA200604578B (en) * | 2003-11-14 | 2008-05-28 | Vertex Pharma | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters |
| AU2005210474B2 (en) * | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CN104788328B (zh) | 2004-06-24 | 2017-09-12 | 沃泰克斯药物股份有限公司 | Atp‑结合弹夹转运蛋白的调控剂 |
| JP5143738B2 (ja) | 2005-08-11 | 2013-02-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子の調節物質 |
| DK2774925T3 (en) * | 2005-11-08 | 2017-02-27 | Vertex Pharma | Heterocyclic modulators of ATP binding cassette transporters |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| WO2007079139A2 (en) | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| ES2398319T3 (es) * | 2005-12-28 | 2013-03-15 | Vertex Pharmaceuticals Incorporated | Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US7645789B2 (en) * | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| EP2007756B1 (en) | 2006-04-07 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| AU2008251504B2 (en) * | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| CA2687764A1 (en) * | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| AU2008302598B2 (en) | 2007-08-24 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis |
| CA2702094C (en) | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
| DK2217572T3 (da) | 2007-11-16 | 2014-02-03 | Vertex Pharma | Isoquinoliner som modulatorer af ATP-bindingskassettetransportører |
| LT2225230T (lt) | 2007-12-07 | 2017-01-25 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzoinės rūgšties kietos formos |
| CN101998854A (zh) * | 2007-12-07 | 2011-03-30 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂 |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| EP2639222B1 (en) * | 2007-12-07 | 2016-08-31 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| CN102245573B (zh) | 2008-02-28 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| JP5622285B2 (ja) | 2008-03-31 | 2014-11-12 | バーテックスファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓｉｎｃｏｒｐｏｒａｔｅｄ | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| CN102164587A (zh) * | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
| DK2349263T3 (da) * | 2008-10-23 | 2014-07-21 | Vertex Pharma | Modulatorer af transmembranledningsevneregulatoren for cystisk fibrose |
| SG10201504084QA (en) | 2009-03-20 | 2015-06-29 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
| EP3381899B1 (en) | 2010-04-22 | 2021-01-06 | Vertex Pharmaceuticals Incorporated | Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds |
| US9270486B2 (en) | 2010-06-07 | 2016-02-23 | Brocade Communications Systems, Inc. | Name services for virtual cluster switching |
| US8989186B2 (en) | 2010-06-08 | 2015-03-24 | Brocade Communication Systems, Inc. | Virtual port grouping for virtual cluster switching |
| US9001824B2 (en) | 2010-05-18 | 2015-04-07 | Brocade Communication Systems, Inc. | Fabric formation for virtual cluster switching |
| US9461840B2 (en) | 2010-06-02 | 2016-10-04 | Brocade Communications Systems, Inc. | Port profile management for virtual cluster switching |
| US9716672B2 (en) | 2010-05-28 | 2017-07-25 | Brocade Communications Systems, Inc. | Distributed configuration management for virtual cluster switching |
| US8867552B2 (en) | 2010-05-03 | 2014-10-21 | Brocade Communications Systems, Inc. | Virtual cluster switching |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| US9628293B2 (en) | 2010-06-08 | 2017-04-18 | Brocade Communications Systems, Inc. | Network layer multicasting in trill networks |
| US9246703B2 (en) | 2010-06-08 | 2016-01-26 | Brocade Communications Systems, Inc. | Remote port mirroring |
| US9608833B2 (en) | 2010-06-08 | 2017-03-28 | Brocade Communications Systems, Inc. | Supporting multiple multicast trees in trill networks |
| US9807031B2 (en) | 2010-07-16 | 2017-10-31 | Brocade Communications Systems, Inc. | System and method for network configuration |
| CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用 |
| US9270572B2 (en) | 2011-05-02 | 2016-02-23 | Brocade Communications Systems Inc. | Layer-3 support in TRILL networks |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| CN103732213A (zh) | 2011-06-07 | 2014-04-16 | 帕里昂科学公司 | 治疗方法 |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| US9401861B2 (en) | 2011-06-28 | 2016-07-26 | Brocade Communications Systems, Inc. | Scalable MAC address distribution in an Ethernet fabric switch |
| US9407533B2 (en) | 2011-06-28 | 2016-08-02 | Brocade Communications Systems, Inc. | Multicast in a trill network |
| US8948056B2 (en) | 2011-06-28 | 2015-02-03 | Brocade Communication Systems, Inc. | Spanning-tree based loop detection for an ethernet fabric switch |
| US8885641B2 (en) | 2011-06-30 | 2014-11-11 | Brocade Communication Systems, Inc. | Efficient trill forwarding |
| US9736085B2 (en) | 2011-08-29 | 2017-08-15 | Brocade Communications Systems, Inc. | End-to end lossless Ethernet in Ethernet fabric |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| US9699117B2 (en) | 2011-11-08 | 2017-07-04 | Brocade Communications Systems, Inc. | Integrated fibre channel support in an ethernet fabric switch |
| IN2014KN00885A (cg-RX-API-DMAC10.html) | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
| US9450870B2 (en) | 2011-11-10 | 2016-09-20 | Brocade Communications Systems, Inc. | System and method for flow management in software-defined networks |
| WO2013093508A2 (en) * | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
| JP2015504920A (ja) | 2012-01-25 | 2015-02-16 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の製剤 |
| US8995272B2 (en) | 2012-01-26 | 2015-03-31 | Brocade Communication Systems, Inc. | Link aggregation in software-defined networks |
| CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
| US9742693B2 (en) | 2012-02-27 | 2017-08-22 | Brocade Communications Systems, Inc. | Dynamic service insertion in a fabric switch |
| US9154416B2 (en) | 2012-03-22 | 2015-10-06 | Brocade Communications Systems, Inc. | Overlay tunnel in a fabric switch |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9374301B2 (en) | 2012-05-18 | 2016-06-21 | Brocade Communications Systems, Inc. | Network feedback in software-defined networks |
| US10277464B2 (en) | 2012-05-22 | 2019-04-30 | Arris Enterprises Llc | Client auto-configuration in a multi-switch link aggregation |
| CN104272668B (zh) | 2012-05-23 | 2018-05-22 | 博科通讯系统有限公司 | 层3覆盖网关 |
| SG11201407867VA (en) | 2012-05-29 | 2014-12-30 | Parion Sciences Inc | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
| CA2874851A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr-mediated disorders |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| US9602430B2 (en) | 2012-08-21 | 2017-03-21 | Brocade Communications Systems, Inc. | Global VLANs for fabric switches |
| US9401872B2 (en) | 2012-11-16 | 2016-07-26 | Brocade Communications Systems, Inc. | Virtual link aggregations across multiple fabric switches |
| ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
| RU2015129065A (ru) | 2012-12-17 | 2017-01-25 | Пэрион Сайенсиз, Инк. | Производные хлор-пиразинкарбоксамида, обладающие активностью блокирования эпителиальных натриевых каналов |
| MX2015007797A (es) | 2012-12-17 | 2015-10-05 | Parion Sciences Inc | Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida. |
| CA2896686A1 (en) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| US9413691B2 (en) | 2013-01-11 | 2016-08-09 | Brocade Communications Systems, Inc. | MAC address synchronization in a fabric switch |
| US9350680B2 (en) | 2013-01-11 | 2016-05-24 | Brocade Communications Systems, Inc. | Protection switching over a virtual link aggregation |
| US9548926B2 (en) | 2013-01-11 | 2017-01-17 | Brocade Communications Systems, Inc. | Multicast traffic load balancing over virtual link aggregation |
| US9565113B2 (en) | 2013-01-15 | 2017-02-07 | Brocade Communications Systems, Inc. | Adaptive link aggregation and virtual link aggregation |
| US9565099B2 (en) | 2013-03-01 | 2017-02-07 | Brocade Communications Systems, Inc. | Spanning tree in fabric switches |
| WO2014145750A1 (en) | 2013-03-15 | 2014-09-18 | Brocade Communications Systems, Inc. | Scalable gateways for a fabric switch |
| US9699001B2 (en) | 2013-06-10 | 2017-07-04 | Brocade Communications Systems, Inc. | Scalable and segregated network virtualization |
| US9565028B2 (en) | 2013-06-10 | 2017-02-07 | Brocade Communications Systems, Inc. | Ingress switch multicast distribution in a fabric switch |
| CN104224781B (zh) * | 2013-06-21 | 2018-09-25 | 中国医学科学院医药生物技术研究所 | 一组2-酰胺基-3-烷氧基取代的吡啶类化合物及其新用途 |
| EP3027590A1 (en) * | 2013-07-31 | 2016-06-08 | Minoryx Therapeutics S.L. | Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof |
| US9912612B2 (en) | 2013-10-28 | 2018-03-06 | Brocade Communications Systems LLC | Extended ethernet fabric switches |
| KR102280372B1 (ko) | 2013-11-12 | 2021-07-22 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법 |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| US9548873B2 (en) | 2014-02-10 | 2017-01-17 | Brocade Communications Systems, Inc. | Virtual extensible LAN tunnel keepalives |
| US10581758B2 (en) | 2014-03-19 | 2020-03-03 | Avago Technologies International Sales Pte. Limited | Distributed hot standby links for vLAG |
| US10476698B2 (en) | 2014-03-20 | 2019-11-12 | Avago Technologies International Sales Pte. Limited | Redundent virtual link aggregation group |
| JP6543268B2 (ja) | 2014-04-15 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物 |
| US10063473B2 (en) | 2014-04-30 | 2018-08-28 | Brocade Communications Systems LLC | Method and system for facilitating switch virtualization in a network of interconnected switches |
| US9800471B2 (en) | 2014-05-13 | 2017-10-24 | Brocade Communications Systems, Inc. | Network extension groups of global VLANs in a fabric switch |
| US10616108B2 (en) | 2014-07-29 | 2020-04-07 | Avago Technologies International Sales Pte. Limited | Scalable MAC address virtualization |
| US9544219B2 (en) | 2014-07-31 | 2017-01-10 | Brocade Communications Systems, Inc. | Global VLAN services |
| US9807007B2 (en) | 2014-08-11 | 2017-10-31 | Brocade Communications Systems, Inc. | Progressive MAC address learning |
| US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| US9524173B2 (en) | 2014-10-09 | 2016-12-20 | Brocade Communications Systems, Inc. | Fast reboot for a switch |
| US9699029B2 (en) | 2014-10-10 | 2017-07-04 | Brocade Communications Systems, Inc. | Distributed configuration management in a switch group |
| KR102788925B1 (ko) | 2014-10-31 | 2025-04-02 | 애브비 에스.에이.알.엘. | 치환된 크로만 및 이의 사용 방법 |
| US9567322B2 (en) | 2014-10-31 | 2017-02-14 | Abbvie S.Á.R.L. | Substituted tetrahydropyrans and method of use |
| PL3221692T3 (pl) | 2014-11-18 | 2021-12-06 | Vertex Pharmaceuticals Inc. | Sposób przeprowadzania testowania o wysokiej przepustowości za pomocą wysokosprawnej chromatografii cieczowej |
| US9626255B2 (en) | 2014-12-31 | 2017-04-18 | Brocade Communications Systems, Inc. | Online restoration of a switch snapshot |
| US9628407B2 (en) | 2014-12-31 | 2017-04-18 | Brocade Communications Systems, Inc. | Multiple software versions in a switch group |
| US10003552B2 (en) | 2015-01-05 | 2018-06-19 | Brocade Communications Systems, Llc. | Distributed bidirectional forwarding detection protocol (D-BFD) for cluster of interconnected switches |
| US9942097B2 (en) | 2015-01-05 | 2018-04-10 | Brocade Communications Systems LLC | Power management in a network of interconnected switches |
| CN104788423B (zh) * | 2015-03-13 | 2016-10-26 | 成都理工大学 | 一种新的囊性纤维化跨膜传导调节因子抑制剂 |
| US10038592B2 (en) | 2015-03-17 | 2018-07-31 | Brocade Communications Systems LLC | Identifier assignment to a new switch in a switch group |
| US9807005B2 (en) | 2015-03-17 | 2017-10-31 | Brocade Communications Systems, Inc. | Multi-fabric manager |
| US10579406B2 (en) | 2015-04-08 | 2020-03-03 | Avago Technologies International Sales Pte. Limited | Dynamic orchestration of overlay tunnels |
| US10439929B2 (en) | 2015-07-31 | 2019-10-08 | Avago Technologies International Sales Pte. Limited | Graceful recovery of a multicast-enabled switch |
| US10171303B2 (en) | 2015-09-16 | 2019-01-01 | Avago Technologies International Sales Pte. Limited | IP-based interconnection of switches with a logical chassis |
| US9912614B2 (en) | 2015-12-07 | 2018-03-06 | Brocade Communications Systems LLC | Interconnection of switches based on hierarchical overlay tunneling |
| JP2019533022A (ja) | 2016-10-24 | 2019-11-14 | ユマニティ セラピューティクス，インコーポレーテッド | 化合物及びその使用 |
| ES3025460T3 (en) | 2017-01-06 | 2025-06-09 | Janssen Pharmaceutica Nv | Scd inhibitor for the treatment of neurological disorders |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| KR102718287B1 (ko) | 2017-11-14 | 2024-10-16 | 머크 샤프 앤드 돔 엘엘씨 | 인돌아민 2,3-디옥시게나제 (ido) 억제제로서의 신규 치환된 비아릴 화합물 |
| EP3768269B1 (en) * | 2018-03-23 | 2025-08-20 | Janssen Pharmaceutica NV | Compounds and uses thereof |
| WO2020049189A1 (en) | 2018-09-09 | 2020-03-12 | Qanatpharma Gmbh | Use of cftr modulators for treating cerebrovascular conditions |
| WO2020154571A1 (en) | 2019-01-24 | 2020-07-30 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| CA3134510A1 (en) * | 2019-03-22 | 2020-10-01 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| WO2024072793A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| WO2024072794A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| WO2024148267A1 (en) * | 2023-01-05 | 2024-07-11 | Empathbio, Inc. | Heterocyclic propyl amine modulators of monoaminergic transporters |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3263567D1 (en) * | 1981-12-14 | 1985-06-20 | Medea Res Srl | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
| IT1226048B (it) * | 1981-12-14 | 1990-12-10 | Medea Res Srl | Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| WO2001046165A2 (en) * | 1999-12-16 | 2001-06-28 | Novartis Ag | N-heteroaryl-amides and their use as parasiticides |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| NZ538809A (en) | 2002-09-30 | 2008-06-30 | Univ California | Thiazolidinone cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| US20050113423A1 (en) | 2003-03-12 | 2005-05-26 | Vangoor Frederick F. | Modulators of ATP-binding cassette transporters |
| ES2887054T3 (es) | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| WO2004110352A2 (en) | 2003-05-16 | 2004-12-23 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| RU2006111093A (ru) | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| WO2005035514A2 (en) * | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| ZA200604578B (en) | 2003-11-14 | 2008-05-28 | Vertex Pharma | Thiazoles and oxazoles.useful as modulators of ATP Binding cassette transporters |
| AU2005210474B2 (en) * | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| US7977322B2 (en) * | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CA2561560A1 (en) | 2004-03-30 | 2005-10-13 | The Regents Of The University Of California | Hydrazide-containing cftr inhibitor compounds and uses thereof |
| US7939558B2 (en) | 2004-06-04 | 2011-05-10 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN104788328B (zh) | 2004-06-24 | 2017-09-12 | 沃泰克斯药物股份有限公司 | Atp‑结合弹夹转运蛋白的调控剂 |
| WO2006044456A1 (en) | 2004-10-13 | 2006-04-27 | Ptc Therapeutics, Inc. | Compounds for nonsense suppression, and methods for their use |
| WO2006099256A2 (en) | 2005-03-11 | 2006-09-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| MX2007011512A (es) | 2005-03-18 | 2007-12-07 | Univ California | Compuestos que tienen actividad para corregir procesamiento de cftr-mutante y usos de los mismos. |
| DK1874306T3 (da) | 2005-04-08 | 2012-10-01 | Ptc Therapeutics Inc | Sammensætninger af en oralt aktiv 1,2,4-oxadiazol til nonsens-mutationssuppressionsterapi |
| CA2609392A1 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| JP5143738B2 (ja) | 2005-08-11 | 2013-02-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子の調節物質 |
| CA2624683A1 (en) * | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| DK2774925T3 (en) | 2005-11-08 | 2017-02-27 | Vertex Pharma | Heterocyclic modulators of ATP binding cassette transporters |
| US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| EP1979367A2 (en) | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| CA2635214A1 (en) * | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in cftr assays and methods therewith |
| ES2398319T3 (es) * | 2005-12-28 | 2013-03-15 | Vertex Pharmaceuticals Incorporated | Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| WO2007079139A2 (en) * | 2005-12-28 | 2007-07-12 | Vertex Pharmaceuticals, Inc. | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| EP2007756B1 (en) * | 2006-04-07 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US7645789B2 (en) * | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| JP2009536969A (ja) * | 2006-05-12 | 2009-10-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｎ−［２，４−ビス（１，１−ジメチルエチル）−５−ヒドロキシフェニル］−１，４−ジヒドロ−４−オキソキノリン−３−カルボキサミド組成物 |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) * | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| JP2010510974A (ja) * | 2006-11-27 | 2010-04-08 | ノバルティス アーゲー | 置換ジヒドロイミダゾールおよび腫瘍の処置におけるその使用 |
| AU2008251504B2 (en) * | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| CA2688004C (en) | 2007-05-25 | 2016-07-05 | Vertex Pharmaceuticals Incorporated | Thienopyridone compounds for use as modulators of cystic fibrosis transmembrane conductance regulator |
| WO2009023509A2 (en) | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
| AU2008302598B2 (en) * | 2007-08-24 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis |
| BRPI0816345A2 (pt) | 2007-09-14 | 2015-02-24 | Vertex Pharma | Formas sólidas de n-[2,4-bis-(1,1-dimetiletil)-5-hidroxifenil]-1,4-diidro-4-o xoquinolin-3-carboxamida |
| CA2699382C (en) | 2007-09-14 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| DK2217572T3 (da) | 2007-11-16 | 2014-02-03 | Vertex Pharma | Isoquinoliner som modulatorer af ATP-bindingskassettetransportører |
| CN101998854A (zh) * | 2007-12-07 | 2011-03-30 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂 |
| EP2639222B1 (en) * | 2007-12-07 | 2016-08-31 | Vertex Pharmaceuticals Incorporated | Process for producing cycloalkylcarboxiamido-pyridine benzoic acids |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| LT2225230T (lt) | 2007-12-07 | 2017-01-25 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il) benzoinės rūgšties kietos formos |
| AU2008335031B2 (en) * | 2007-12-13 | 2013-11-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN102245573B (zh) | 2008-02-28 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 作为cftr调节剂的杂芳基衍生物 |
| JP5622285B2 (ja) | 2008-03-31 | 2014-11-12 | バーテックスファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓｉｎｃｏｒｐｏｒａｔｅｄ | Ｃｆｔｒモジュレーターとしてのピリジル誘導体 |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) * | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| RS61408B1 (sr) | 2008-08-13 | 2021-03-31 | Vertex Pharma | Farmaceutska kompozicija i njeno ordiniranje |
| CN102164587A (zh) * | 2008-09-29 | 2011-08-24 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的剂量单元 |
| DK2349263T3 (da) * | 2008-10-23 | 2014-07-21 | Vertex Pharma | Modulatorer af transmembranledningsevneregulatoren for cystisk fibrose |
| US20110257223A1 (en) | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| PL2358680T3 (pl) | 2008-10-23 | 2013-08-30 | Vertex Pharma | Stałe postacie N-(4-(7-azabicyklo[2.2.1]heptan-7-ylo)-2-(trifluorometylo)fenylo)-4-okso-5-(trifluorometylo)-1,4-dihydrochinolino-3-karboksyamidu |
| WO2010048564A1 (en) * | 2008-10-23 | 2010-04-29 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010078103A1 (en) | 2008-12-30 | 2010-07-08 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| SMT201800416T1 (it) | 2009-03-20 | 2018-09-13 | Vertex Pharma | Modulatori del regolatore di conduttanza trans-membrana della fibrosi cistica |
| SG10201504084QA (en) * | 2009-03-20 | 2015-06-29 | Vertex Pharma | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| KR20120083416A (ko) | 2009-09-17 | 2012-07-25 | 버텍스 파마슈티칼스 인코포레이티드 | 아자비시클릭 화합물의 제조 방법 |
| MX2012004792A (es) * | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| CN102666546B (zh) | 2009-10-23 | 2015-09-09 | 沃泰克斯药物股份有限公司 | N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式 |
| JP5789611B2 (ja) | 2009-10-23 | 2015-10-07 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス |
| US8471029B2 (en) | 2010-03-19 | 2013-06-25 | Vertex Pharmaceutical Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN102892764B (zh) | 2010-03-25 | 2016-07-06 | 弗特克斯药品有限公司 | (r)-1(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1h-吲哚-5-基)环丙烷甲酰胺的固体形式 |
| CN102933206A (zh) | 2010-04-07 | 2013-02-13 | 弗特克斯药品有限公司 | 3-(6-(1-(2，2-二氟苯并[d][1，3]二氧杂环戊烯-5-基)环丙烷甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
| EP3381899B1 (en) | 2010-04-22 | 2021-01-06 | Vertex Pharmaceuticals Incorporated | Intermediate compound for process of producing cycloalkylcarboxamido-indole compounds |
| CA2796642A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| WO2011133956A1 (en) | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| NZ603043A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| AR081920A1 (es) | 2010-05-20 | 2012-10-31 | Vertex Pharma | Procesos de produccion de moduladores del regulador de conductancia transmembrana de fibrosis quistica |
| AU2011255237A1 (en) | 2010-05-20 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| JP2013536231A (ja) | 2010-08-23 | 2013-09-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与 |
| US20120064157A1 (en) | 2010-08-27 | 2012-03-15 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| IN2014KN00885A (cg-RX-API-DMAC10.html) | 2011-11-08 | 2015-10-02 | Vertex Pharma | |
| JP2015504920A (ja) | 2012-01-25 | 2015-02-16 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の製剤 |
| US20130217020A1 (en) | 2012-02-22 | 2013-08-22 | National Health Research Institutes | Methods for improving sensitivity and specificity of screening assays of kras codons 12 and 13 mutations |
| CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
-
2009
- 2009-03-25 JP JP2011502011A patent/JP5622285B2/ja active Active
- 2009-03-25 AU AU2009231993A patent/AU2009231993B2/en active Active
- 2009-03-25 CN CN200980111627.1A patent/CN101981011B/zh active Active
- 2009-03-25 ES ES09728176.0T patent/ES2442945T3/es active Active
- 2009-03-25 NZ NZ600772A patent/NZ600772A/xx unknown
- 2009-03-25 WO PCT/US2009/038203 patent/WO2009123896A1/en not_active Ceased
- 2009-03-25 HU HUE12188920A patent/HUE026220T2/en unknown
- 2009-03-25 CN CN201410128427.XA patent/CN103951614A/zh active Pending
- 2009-03-25 SI SI200931290T patent/SI2615085T1/sl unknown
- 2009-03-25 NZ NZ588006A patent/NZ588006A/xx unknown
- 2009-03-25 PL PL12188920T patent/PL2615085T3/pl unknown
- 2009-03-25 EP EP15182081.8A patent/EP2980077B1/en active Active
- 2009-03-25 US US12/410,725 patent/US8227615B2/en active Active
- 2009-03-25 DK DK12188920.8T patent/DK2615085T3/en active
- 2009-03-25 PT PT121889208T patent/PT2615085E/pt unknown
- 2009-03-25 CA CA2718310A patent/CA2718310C/en active Active
- 2009-03-25 ES ES12188920.8T patent/ES2552990T3/es active Active
- 2009-03-25 NZ NZ61609709A patent/NZ616097A/en unknown
- 2009-03-25 EP EP12188920.8A patent/EP2615085B1/en active Active
- 2009-03-25 EP EP09728176.0A patent/EP2271621B1/en active Active
-
2012
- 2012-06-26 US US13/533,326 patent/US8524910B2/en active Active
-
2013
- 2013-08-02 US US13/957,678 patent/US8889875B2/en active Active
-
2014
- 2014-02-03 JP JP2014018199A patent/JP5930487B2/ja active Active
- 2014-11-28 HK HK14112053.3A patent/HK1198537A1/xx unknown
-
2015
- 2015-04-23 JP JP2015088075A patent/JP2015131860A/ja not_active Withdrawn
- 2015-10-27 HR HRP20151141TT patent/HRP20151141T1/hr unknown
- 2015-11-19 CY CY20151101042T patent/CY1116953T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011516420A5 (cg-RX-API-DMAC10.html) | ||
| JP2011513321A5 (cg-RX-API-DMAC10.html) | ||
| JP2011505338A5 (cg-RX-API-DMAC10.html) | ||
| JP2010539185A5 (cg-RX-API-DMAC10.html) | ||
| NZ746793A (en) | Silicone atoms containing ivacaftor analogues | |
| JP2012521361A5 (cg-RX-API-DMAC10.html) | ||
| JP2013508414A5 (cg-RX-API-DMAC10.html) | ||
| JP2019513741A5 (cg-RX-API-DMAC10.html) | ||
| RU2011122646A (ru) | Модуляторы переносчиков атф-связывающих кассет | |
| SI3091011T1 (en) | Modulators of ATP conveyor belt conveyors | |
| JP2012514038A5 (cg-RX-API-DMAC10.html) | ||
| RU2010114732A (ru) | Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида | |
| HRP20151141T1 (hr) | Derivati piridila kao modulatori cftr | |
| NZ732701A (en) | Compounds, compositions, and methods for increasing cftr activity | |
| IL273752B2 (en) | Ingredients, compounds and methods for increasing CFTR activity | |
| RU2014123381A (ru) | Модуляторы транспортеров атф-связывающей кассеты | |
| DK2709986T3 (en) | DEUTERATED DERIVATIVES OF IVACAFTOR | |
| HRP20210165T1 (hr) | Čvrsta disperzija amorfnog oblika (r)-1(2,2-difluorobenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluoro-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamida | |
| JP2007519740A5 (cg-RX-API-DMAC10.html) | ||
| JP2012521362A5 (cg-RX-API-DMAC10.html) | ||
| JP2013508407A5 (cg-RX-API-DMAC10.html) | ||
| NZ603044A (en) | Pharmaceutical compositions comprising cftr modulators and administrations thereof | |
| RU2006120549A (ru) | Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты | |
| JP2013501787A5 (cg-RX-API-DMAC10.html) | ||
| JP2009522277A5 (cg-RX-API-DMAC10.html) |